OGINasdaqPharmaceutical PreparationsFiscal year ends September 30
ORGANIGRAM GLOBAL INC.
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 40-F on Dec 16, 2025
$0.94+0.02 (+1.73%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Organigram Global has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Organigram Global filed with the SEC
Organigram Global to Host 2026 OG Investor Session
EX-99.1 to Form 6-K
Item One - Name and Address of Company
EX-99.1 to Form 6-K
(1) [ Redacted - Personal Information ],
EX-99.2 to Form 6-K
(1) [ Redacted - Personal Information ],
EX-99.3 to Form 6-K
Condensed Consolidated Interim Statements of Financial Position
EX-99.2 to Form 6-K
Organigram to Report Third Quarter Fiscal 2026 Results on August 11, 2026
EX-99.1 to Form 6-K
Condensed Consolidated Interim Statements of Financial Position
EX-99.2 to Form 6-K
Organigram to Report Second Quarter Fiscal 2026 Results on May 12th, 2026
EX-99.1 to Form 6-K
Annual General and Special Meeting of Shareholders
EX-99.2 to Form 6-K
NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING
EX-99.1 to Form 6-K
March 30, 2026 at 10:00 AM (Canada/Eastern Standard)
EX-99.2 to Form 6-K
Item One – Name and Address of Company
EX-99.1 to Form 6-K
Share Sale and Purchase Agreement
EX-99.1 to Form 6-K
ARTICLE 1 DEFINITIONS AND INTERPRETATION 1
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Condensed Consolidated Interim Statements of Financial Position
EX-99.2 to Form 6-K
Organigram to Report First Quarter Fiscal 2026 Results on February 10, 2026
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Organigram Extends Innovation Investment with Phylos
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K